BACKGROUND: Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating its clinical utility. We seek to assess the clinical utility of Decipher Biopsy in localized PCa patients. METHODS: A multi-institutional study of 855 men who underwent Decipher Biopsy testing between February 2015 and October 2019. All patients were tracked through the prospective Michigan Urological Surgery Improvement Collaborative and linked to the Decipher Genomics Resource Information Database (GRID®; NCT02609269). Patient matching was performed by an independent third-party (ArborMetrix Inc.) using two or more unique identifiers. Cumulative incidence curves for time to treatment (TTT) and time to failure (TTF) were constructed using Kaplan-Meier estimates. Multivariable Cox proportional hazard models were used to evaluate the independent association of high-risk Decipher scores with the conversion from AS to radical therapy and treatment failure (biochemical failure or receipt of salvage therapy). RESULTS AND LIMITATIONS: Eight hundred fifty-five patients underwent Decipher Biopsy testing during the study period. Of the 855 men, 264 proceeded to AS (31%), and 454 (53%) received radical therapy. In men electing AS, after adjusting for NCCN risk group, age, PSA, prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT (HR 2.51, 95% CI 1.52-4.13 p < 0.001). Similarly, in patients that underwent radical therapy, a high-risk Decipher score was independently associated with TTF (HR 2.98, 95% CI 1.22-7.29, p = 0.01) on multivariable analysis. Follow-up time was a limitation. CONCLUSION: In a prospective statewide registry, high-risk Decipher Biopsy score was strongly and independently associated with conversion from AS to definitive treatment and treatment failure. These real-world data support the clinical utility of Decipher Biopsy. An ongoing phase 3 randomized trial (NCT04396808) will provide level 1 evidence of the clinical impact of Decipher biopsy testing.
BACKGROUND: Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating its clinical utility. We seek to assess the clinical utility of Decipher Biopsy in localized PCa patients. METHODS: A multi-institutional study of 855 men who underwent Decipher Biopsy testing between February 2015 and October 2019. All patients were tracked through the prospective Michigan Urological Surgery Improvement Collaborative and linked to the Decipher Genomics Resource Information Database (GRID®; NCT02609269). Patient matching was performed by an independent third-party (ArborMetrix Inc.) using two or more unique identifiers. Cumulative incidence curves for time to treatment (TTT) and time to failure (TTF) were constructed using Kaplan-Meier estimates. Multivariable Cox proportional hazard models were used to evaluate the independent association of high-risk Decipher scores with the conversion from AS to radical therapy and treatment failure (biochemical failure or receipt of salvage therapy). RESULTS AND LIMITATIONS: Eight hundred fifty-five patients underwent Decipher Biopsy testing during the study period. Of the 855 men, 264 proceeded to AS (31%), and 454 (53%) received radical therapy. In men electing AS, after adjusting for NCCN risk group, age, PSA, prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT (HR 2.51, 95% CI 1.52-4.13 p < 0.001). Similarly, in patients that underwent radical therapy, a high-risk Decipher score was independently associated with TTF (HR 2.98, 95% CI 1.22-7.29, p = 0.01) on multivariable analysis. Follow-up time was a limitation. CONCLUSION: In a prospective statewide registry, high-risk Decipher Biopsy score was strongly and independently associated with conversion from AS to definitive treatment and treatment failure. These real-world data support the clinical utility of Decipher Biopsy. An ongoing phase 3 randomized trial (NCT04396808) will provide level 1 evidence of the clinical impact of Decipher biopsy testing.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Daniel E Spratt; Jingbin Zhang; María Santiago-Jiménez; Robert T Dess; John W Davis; Robert B Den; Adam P Dicker; Christopher J Kane; Alan Pollack; Radka Stoyanova; Firas Abdollah; Ashley E Ross; Adam Cole; Edward Uchio; Josh M Randall; Hao Nguyen; Shuang G Zhao; Rohit Mehra; Andrew G Glass; Lucia L C Lam; Jijumon Chelliserry; Marguerite du Plessis; Voleak Choeurng; Maria Aranes; Tyler Kolisnik; Jennifer Margrave; Jason Alter; Jennifer Jordan; Christine Buerki; Kasra Yousefi; Zaid Haddad; Elai Davicioni; Edouard J Trabulsi; Stacy Loeb; Ashutosh Tewari; Peter R Carroll; Sheila Weinmann; Edward M Schaeffer; Eric A Klein; R Jeffrey Karnes; Felix Y Feng; Paul L Nguyen Journal: J Clin Oncol Date: 2017-11-29 Impact factor: 44.544
Authors: Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Jeffrey J Tosoian; Mufaddal Mamawala; Jonathan I Epstein; Patricia Landis; Katarzyna J Macura; Demetrios N Simopoulos; H Ballentine Carter; Michael A Gorin Journal: Eur Urol Date: 2020-01-07 Impact factor: 20.096
Authors: Alejandro Berlin; Jure Murgic; Ali Hosni; Melania Pintilie; Adriana Salcedo; Michael Fraser; Suzanne Kamel-Reid; Jingbin Zhang; Qiqi Wang; Carolyn Ch'ng; Samineh Deheshi; Elai Davicioni; Theodorus van der Kwast; Paul C Boutros; Robert G Bristow; Melvin L K Chua Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-29 Impact factor: 7.038
Authors: Daniel E Spratt; Kasra Yousefi; Samineh Deheshi; Ashley E Ross; Robert B Den; Edward M Schaeffer; Bruce J Trock; Jingbin Zhang; Andrew G Glass; Adam P Dicker; Firas Abdollah; Shuang G Zhao; Lucia L C Lam; Marguerite du Plessis; Voleak Choeurng; Zaid Haddad; Christine Buerki; Elai Davicioni; Sheila Weinmann; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Felix Y Feng Journal: J Clin Oncol Date: 2017-03-30 Impact factor: 44.544
Authors: Matthew R Cooperberg; Elai Davicioni; Anamaria Crisan; Robert B Jenkins; Mercedeh Ghadessi; R Jeffrey Karnes Journal: Eur Urol Date: 2014-07-02 Impact factor: 20.096
Authors: Peter E Lonergan; Samuel L Washington; Janet E Cowan; Shoujun Zhao; Hao G Nguyen; Katsuto Shinohara; Matthew R Cooperberg; Peter R Carroll Journal: J Urol Date: 2020-06-10 Impact factor: 7.450